top of page

EGFR inhibitors 

(e.g., osimertinib)

Cardio-oncological evaluation*

before cancer treatment begins

Cardio-oncological evaluation* AND Home blood pressure monitoring for crizotinib, brigatinib and lorlatinib

every 3 months for 1 year, then every 6 months during cancer treatment

* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.

​

bottom of page